Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5528102 | 0.86 | SMN1; SMN2 (0.48) | KMT2AHTTSMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL5530855 | 0.86 | KMT2A (0.56) | KMT2AHTTSMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL5521827 | 0.86 | ALDH1A1 (0.53) | ATMALDH1A1 | |
| SCHEMBL5522924 | 0.84 | POLB (0.41) | KMT2AHTTSMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL5518068 | 0.84 | HSP90AA1 (0.40) | KMT2AHTTSMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL5517436 | 0.83 | SMN1; SMN2 (0.39) | KMT2AHTTSMN1; SMN2ATMMAPT | |
| SCHEMBL5525595 | 0.83 | SMN1; SMN2 (0.43) | KMT2AHTTSMN1; SMN2ATMLMNA | |
| SCHEMBL5515940 | 0.83 | TDP1 (0.41) | KMT2AHTTSMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL5519504 | 0.83 | RAB9A (0.44) | KMT2AHTTSMN1; SMN2ATMTP53 | |
| SCHEMBL5521910 | 0.83 | ALDH1A1 (0.42) | HTTSMN1; SMN2LMNAMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155744-A1 | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P, ANGELETTI S.P.A. (IT) | 2007-07-05 | — | — | US | claimed |
| US-20070155744-A1 | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P, ANGELETTI S.P.A. (IT) | 2007-07-05 | — | — | US | disclosed |
| US-20070155744-A1 | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P, ANGELETTI S.P.A. (IT) | 2007-07-05 | — | — | US | disclosed |
| US-20070155744-A1 | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P, ANGELETTI S.P.A. (IT) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155744-A1 | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors | DUT, NQO2, TYMP | KMT2A 469/4885HTT 3870/4885SMN1; SMN2 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.